Please login to the form below

Not currently logged in
Email:
Password:

Dapagliflozin meets goals of late-stage study

Bristol-Myers Squibb and AstraZeneca's diabetes drug dapagliflozin has met the main goals of a phase III trial

BMS and AZ's diabetes drug dapagliflozin met the main goals of a phase III trial. It was proven that the drug was more effective than an older treatment at reducing blood sugar levels.

Dapagliflozin is a first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor being developed as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes.

The trial enrolled 597 patients with type 2 diabetes that was inadequately controlled with at least half the recommended dose of glimepiride. The companies said a combination of dapagliflozin and glimepiride was better at reducing blood sugar levels than glimepiride and a placebo.

Patients on dapagliflozin also lost more weight, had greater oral glucose tolerance and lower blood sugar levels between meals after the 24-week late stage clinical trial.

Side-effects were similar for dapagliflozin and glimepiride, but patients on dapagliflozin were more likely to have genital tract infections.

Results from the trial were presented at a meeting of the European Association for the Study of Diabetes in Stockholm.

21st September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics